RT Journal Article
SR Electronic
T1 Comprehensive Analysis of Cell-Free DNA Fragmentation Across Cancer Stages
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.07.23298181
DO 10.1101/2023.11.07.23298181
A1 Guo, Xin
A1 Nie, Lijuan
A1 Yan, Junjun
A1 Ling, Tinsheng
A1 Zhang, Fei
A1 Chen, Yi
A1 Li, Mengyu
A1 Zeng, Wenqi
A1 Chen, Yugen
A1 Chu, Wen-Ming
A1 Ge, Olivia
A1 Guo, Qing
A1 Ge, Dongliang
A1 Zhou, Xiqiao
YR 2023
UL http://medrxiv.org/content/early/2023/11/08/2023.11.07.23298181.abstract
AB Circulating cell-free DNA (cfDNA) in the bloodstream displays cancer-derived fragmentation patterns, offering a non-invasive diagnostic avenue for cancer patients. However, the association between cfDNA fragmentation patterns and cancer progression remains largely unexplored. In this study, we analyzed this relationship using 214 whole-genome cfDNA samples across seven solid cancer types and revealed that the relation between cfDNA fragmentation patterns and cancer stages vary across cancer types. Among them, cfDNA fragmentation patterns in colorectal cancer (CRC) showed a strong correlation with cancer stages. This finding is further validated with an independent targeted cfDNA dataset from 29 CRC samples. Inspired by these findings, we designed “frag2stage”, a machine learning model that exploits cfDNA fragmentation data to differentiate cancer stages of CRC. Evaluated on two independent cfDNA datasets, our model can distinguish cancer stages of CRC with the area under the curve (AUC) values ranging from 0.68 to 0.99. The results suggest that cfDNA fragmentation patterns might carry yet undiscovered genetic and epigenetic signals, highlighting their promising potential for broader diagnostic applications in oncology.Competing Interest StatementX.G., F.Z., W.Z. and D.G. are shareholders of Apostle Inc and Apostle China Ltd. A patent that incorporates a portion of the research presented in this work has been filed.Funding StatementApostle IncAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee/IRB of the First Affiliated Hospital of Nanjing Medical University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.